BZKF study groups

Clinical study groups are responsible for conducting clinical trials on patients with certain characteristics of cancer. Clinical study groups can be grouped around a particular methodology or focus on the treatment of a disease at a specific stage. However, clinical study groups are often a mixture of both. In terms of content, the clinical study groups apply the following measures and instruments:

• Rapid and effective testing of innovative, translational approaches from the research laboratories and development departments of the university hospitals for the prophylaxis, diagnosis and treatment of cancer with a focus on networked pilot studies (phase I/II)
• Validation of promising approaches from Phase I/II study concepts in targeted Phase III Drug Act (AMG) or Medical Devices Act (MPG) studies, also in cooperation with local industrial partners
• Networked patient-oriented research with the aim of testing and further developing research hypotheses, particularly in the development of biomarkers or other predictive features
• Epidemiological testing of the effectiveness and tolerability of new measures for the early detection, prophylaxis, diagnosis and treatment of cancer
• Investigation of the quality of life of patients with cancer with a focus on networked outcome studies using epidemiological data
• Rapid integration of new knowledge into everyday care following positive assessment by the networked outcome studies

With this structure, the BZKF closes the gap between the findings of basic research and the resulting improvement in established patient care for cancer patients. The Bavarian Center for Cancer Research forms the basis for effective patient-oriented cancer research and the clinical implementation of innovative treatment concepts developed in Bavaria in compliance with the German Medicines Act (AMG) and the German Medical Devices Act (MDR).